KIRUBEL TEFERA
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology CINCINNATI, OH NPI 1558523977
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology OH NOVARTIS PHARMACEUTICALS CORPORATION All categories
General Payments — all program years on this page
$1,840.72
- Category: General Payments
- Program years: PY2018–2024
- Record count: 69
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $866.30 across 40 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $866.30 | 40 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $154.74 | 7 |
| Acerta Pharma LLC | $103.33 | 4 |
| GlaxoSmithKline, LLC. | $80.61 | 4 |
| PFIZER INC. | $70.25 | 3 |
| AVEO Pharmaceuticals, Inc. | $41.35 | 2 |
| Sumitomo Pharma America, Inc. | $38.07 | 2 |
| TerSera Therapeutics LLC | $37.84 | 1 |
| Kite Pharma, Inc. | $33.37 | 1 |
| Ipsen Biopharmaceuticals, Inc | $28.82 | 1 |
| Agios Pharmaceuticals, Inc. | $22.77 | 1 |
| Incyte Corporation | $22.15 | 1 |
| Astellas Pharma US Inc | $22.01 | 1 |
| JAZZ PHARMACEUTICALS INC. | $20.37 | 1 |
| Lilly USA, LLC | $19.67 | 1 |
| Karyopharm Therapeutics Inc. | $18.90 | 1 |
| E.R. Squibb & Sons, L.L.C. | $18.83 | 1 |
| Daiichi Sankyo Inc. | $18.50 | 1 |
| Stemline Therapeutics Inc. | $18.38 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $17.61 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $17.58 | 1 |
| Merck Sharp & Dohme Corporation | $16.24 | 1 |
| Melinta Therapeutics, Inc. | $16.21 | 1 |
| Janssen Biotech, Inc. | $15.50 | 1 |
| Genentech USA, Inc. | $13.20 | 1 |
By program year
Records — PY2024 (40)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.